Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 88Terminated 42Recruiting 40Active not recruiting 20Unknown 7Withdrawn 5No longer available 2Suspended 1Not yet recruiting 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 17Genitourinary 4Thoracic 2Sarcoma 2Gastrointestinal 2Breast 2Head & Neck 1Gynecologic 1Endocrine 1CNS 1

Conditions

Glioblastoma 19Glioma 14Brain Neoplasms 13Astrocytoma 4Neoplasms 3Meningioma 2Gliosarcoma 2Diffuse Intrinsic Pontine Glioma 2Venous Thromboembolism 1Surgical Wound Infection 1Stroke 1Spinal Diseases 1Spinal Cord Neoplasms 1Seizures 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroma, Acoustic 1Neuroma 1Neurofibromatosis 1 1Neurofibromatoses 1Neuroblastoma 1Neurilemmoma 1Motor Activity 1Melanoma 1Lymphoma, Follicular 1Liver Neoplasms 1Intracranial Hypertension 1Hydrocephalus 1

Interventions

pembrolizumab 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Melanoma × CNS × Clear all
NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

University of Florida

Phase 1/2 Suspended
29 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡